| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514130800 | Platelet aggregation or adhesion affecting | 22 |
| 20110034389 | ACTIVE AGENTS, COMPOSITIONS, AND METHODS FOR INHIBITING AND REVERSING PLATELET FUNCTION - Active agents, compositions, and methods for inhibiting and reversing platelet function are provided herein. In particular embodiments, the active agents provided herein inhibit or reverse platelet function. In particular embodiments, the compositions described herein are pharmaceutical formulations. Methods of inhibiting and reversing platelet function are also provided herein. In particular embodiments, methods as described herein include administration of a Sema3E polypeptide. Further, methods of treating pathologic conditions associated with platelet function (i.e., platelet activation) and methods of screening active agent candidates are also provided. | 02-10-2011 |
| 20110039780 | PLATELET GLYCOPROTEIN IB ALPHA VARIANT FUSION POLYPEPTIDES AND METHODS OF USE THEREOF - The present invention provides compositions and methods for treating or preventing vascular-associated disorders. | 02-17-2011 |
| 20110071084 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS - The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) | 03-24-2011 |
| 20110118187 | REVERSIBLE PLATELET INHIBITION - The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same. | 05-19-2011 |
| 20110136740 | CYSTINE KNOT PEPTIDES BINDING TO ALPHA IIb BETA 3 INTEGRINS AND METHODS OF USE - Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against α | 06-09-2011 |
| 20110312890 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS - This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements. | 12-22-2011 |
| 20120010143 | ADHESIVE HEMOSTATIC AGENT BASED ON PORCINE ATELOCOLLAGEN AND METHOD FOR PRODUCTION THEREOF - Disclosed is an adhesive hemostatic agent based on non-blood constituents including DOPA, able to strongly adhere to collagen fibers, and which comprises an antifibrinolytic agent in addition to an esterified atelocollagen which is non-immunogenic and may become positively charged thereon such that the adhesive hemostatic agent has no possibility of mediating particular diseases or viral infections (HIV, HCV, HBV, CMV, etc), unlike conventional agents comprising blood constituents, and readily binds to negatively charged platelets at high adhesive strength, thus inducing quick blood coagulation. Also, provided is a method for preparing the same. | 01-12-2012 |
| 20120129776 | Bioactive peptides and method of using same - Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation. | 05-24-2012 |
| 20120208761 | TYPE I-TYPE IV COLLAGEN HYBRID GEL - It is an object of the present invention to provide a Type I-Type IV collagen hybrid gel, which maintains characteristics of a Type IV collagen and is superior in gel strength. It is the Type I-Type IV collagen hybrid gel obtained by mixing 100 to 500 parts by mass of the Type I collagen having fibrosis ability, relative to 100 parts by mass of the Type IV collagen having gelling ability. A three-dimensional structure is formed, where a membrane-like substance by the Type IV collagen is formed onto a fibrous substance by the Type I collagen, so as to be able to provide cell culture environment approximate to a basement membrane of a living body. | 08-16-2012 |
| 20130040886 | Peptides and Methods for Inhibiting G alpha Protein Signaling - The present invention comprises peptide compositions and methods for specifically inhibiting signaling through Gα subunits. | 02-14-2013 |
| 20130040887 | Inhibiting Collagen-Induced Platelet Aggregation and Activation with Peptide Variants - The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect platelets by action on the collagen receptor, glycoprotein VI (GPVI). More specifically, however, the peptides act on the GPVI-FcRγ signaling complex. The invention also provides lipid and sugar conjugated peptides comprising L- or D-amino acids. The invention still further provides a method of designing of the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The present invention further relates to the therapy of various disease states involving the use of these peptides and compounds. Specifically, the peptides and compounds are useful in the treatment and/or prevention of a disease or condition involving platelet activation and aggregation, and more particularly, collagen-induced platelet activation and aggregation. They also are useful in the production of medical devices comprising peptide matrices (i.e., for example, cardiovascular stents). | 02-14-2013 |
| 20130072433 | INHIBITORS OF BETA INTEGRIN-G PROTEIN ALPHA SUBUNIT BINDING INTERACTIONS - Provided herein are compounds that inhibit a binding interaction between a β integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation. | 03-21-2013 |
| 20140357563 | Compositions and Methods for the Generation of Activated Protein C and Methods of Use Thereof - Compositions and methods for generating activated protein C and methods of use thereof are disclosed. | 12-04-2014 |
| 20150031619 | COLLAGEN-BINDING SYNTHETIC PEPTIDOGLYCANS, PREPARATION, AND METHODS OF USE - This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use. | 01-29-2015 |
| 20150038420 | METHODS FOR TREATING PROPERDIN-RELATED DISEASES OR DISORDERS - The present invention relates to methods for treating or preventing a properd related disease or disorder in a subject in need thereof, or for reducing mortality of a subject suffering from a properdin-related disease or disorder, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a properdin protein. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments. | 02-05-2015 |
| 20150105320 | ANTI-ANGIOGENIC TREATMENT OF OVARIAN, BREAST, AND PROSTATE CANCER WITH A COMBINATION OF ANTAGONISTS - The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12). | 04-16-2015 |
| 20150353492 | MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS AND USES THEREOF - This invention is in the field of medicinal chemistry. In particular, the invention relates to mixed disulfide conjugates of thienopyridine compounds, and their use as therapeutics for the treatment, amelioration, and prevention of cardiovascular diseases. | 12-10-2015 |
| 20160074482 | Compositions and Methods for Producing Vascular Occlusion using a Solid-phase Platelet Binding Agent - The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion. | 03-17-2016 |
| 514130900 | Glycoprotein IIb/IIIa affecting | 4 |
| 20110009325 | CRYSTALLINE FORMS OF RAPAMYCIN ANALOGS - Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate. The rampamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof: | 01-13-2011 |
| 20120046230 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor - The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof. | 02-23-2012 |
| 20120115784 | Assessment of Cardiac Health and Thrombotic Risk in a Patient - The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis. | 05-10-2012 |
| 20130316951 | COMPOSITION FOR DISSOLVING THROMBI, AND A PHARMACEUTICAL COMPOSITION FOR TREATING STENOTIC OR OCCLUSIVE VASCULAR DISEASES WHICH COMPRISES THE SAME - The present invention relates to: a composition for dissolving thrombi comprising a peptide comprising the Arg-Gly-Asp motif; a pharmaceutical composition for treating stenotic or occlusive vascular diseases which comprises the same; and a thrombus dissolving method and a method for treating stenotic or occlusive vascular diseases, comprising the step of administering the same. The compositions and methods of the present invention have the advantage that they effectively break down already formed thrombi by adopting the principle of targeting integrin within the thrombus such as platelet surface GPIIb-IIIa, which is not the same as the existing principle of plasminogen activation. Also, the compositions and methods of the present invention have a nerve-protecting function as they effectively open as far as the microvasculature, without the occurrence of restenosis after penetration. | 11-28-2013 |
